当前位置：首页 > 文献互助 > 互助详情

24 conference program-Delivery Of Nucleic Acid Therapeutics II: Biology, Engineering And Development复制

用户fT0JfqFp_Osk 14天前 34 10 已完结

1. 系统已在2025-11-24 16:47:50对应助文件进行删除

2. 如有需要请重新发布求助信息

注: 所有应助的资源仅供学习交流使用, 不得违反相关法律法规

DOI:复制

文献链接:复制

其他信息:

SF Dowdy, L Sepp-Lorenzino, M Stanton
2024
dc.engconfintl.org
Dyne Therapeutics is a clinical-stage muscle disease company focused on advancing innovative
life-transforming therapeutics for people living with genetically driven diseases. With its …

上一篇：CENTYRIN-TARGETED siRNA CONJUGATES FOR EXTRA-HEPATIC DELIVERY: ABX-1100, A CD71 CENTYRIN-GYS1 siRNA CONJUGATE FOR TREATMENT OF …

下一篇：Selective and Potent Molecular Glue Degraders for NIMA-Related Kinase 7

互助时间线

2025-11-22 14:04:14 [完结求助]

系统完结了求助, 已自动确认了jodie0105应助的文件是正确的, 求助状态变成 已完结

2025-11-17 16:47:50 [上传文件]

jodie0105上传了文件(pdf 26.85 MB), 求助状态变成 待确认

2025-11-17 14:04:14 [发起求助]

最新发布的求助

Index Structures for Biological Sequences 3小时前
Drugging the efferocytosis process: concepts and opportunities. 4小时前
Characterization of CAR-T cellular kinetics and efficacy in solid tumor patients with and without prior lymphodepletion chemotherapy using a PBPK-PD model 5小时前
Comprehensive 3d Transition Metal Single‐Atom Modulation Tunes Ni‐MOF D‐Band for Alkaline OER 6小时前
Decoupling of nitrogen, phosphorus, and carbon release from fine and coarse roots during 7 years of decomposition 6小时前
A meta-analysis of albuminuria as a surrogate endpoint for kidney failure 6小时前
Tetrahedral Framework Nucleic Acid-Based Delivery of miR-34a Inhibitor for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis. 7小时前
A practical guide to large-scale docking 7小时前
Bicyclo[1.1.1]pentane-Derived Building Blocks for Click Chemistry 7小时前
Expanding Therapeutic Horizons in Parkinson's Disease Through MicroRNA-Based Interventions: A Comprehensive Review 8小时前
{Formulated Preparations- Specific Monographs} Rivastigmine Capsules - british pharmacopoeia[1731412457.779041.html] 9小时前
Cadonilimab plus platinum-based chemotherapy with or without bevacizumab as first-line treatment for persistent, recurrent, or metastatic cervical cancer (COMPASSION-16): a randomised, double-blind, placebo-controlled phase 3 trial in China 10小时前

wispass工作室 Copyright © 蜀ICP备2024051606号-2 www.wispass.com